

# Neuroplasticity in Opioid Addiction



**JAKE BARNES**  
**WITH DR. MARGRET FLANIGAN AND DR.**  
**BILL FLYNN**

# Introduction



- Opioid: class of prescription drug used for pain diarrhea, cough suppression, recreational used for euphoric high (ex. heroin)
  - High abuse potential and addiction rate
  - Desensitization and withdraw occur with chronic use

# Outline





- Endogenous Opioid System (EOS)
- Opioid Receptors
- Neural Changes

# EOS



- Endogenous opioids bind to opioid receptors to inhibit the release of neurotransmitter
- Receptors usually on GABA neurons, so they stop inhibition
- Generally results in the release of dopamine for pain modulation, euphoric feelings

# Mechanism of Action for Opioid Receptors




Source: Nelson LS, Lewin NA, Howland MA, Hoffman RS, Goldfrank LR, Flomenbaum NE: *Goldfrank's Toxicologic Emergencies, 9th Edition*: <http://www.accessmedicine.com>

Copyright © The McGraw-Hill Companies, Inc. All rights reserved.

<http://jenniferbates.blogspot.com/2010/06/like-action-potential.html>

# Endogenous opioid affinities for opioid receptors



Thicker arrows indicate higher affinities for receptors

# Opioid Receptors



- **Mu:**
  - most important receptor
  - Target of nearly all drugs
  - Internalization with chronic exogenous opioids (Bailey and Connor, 2005)
- **Kappa**
  - Some role in pain modulation
  - Can cause dysphoria, ↑ with cocaine withdraw
- **Delta**
  - Some supraspinal analgesia
  - May colocalize with CRF peptides (Williams and Milner, 2011)
    - ✦ Implications for stress in withdraw
  - Competitive inhibition of mu receptors and heterodimerization with mu receptors: desensitization

# Physiological effects of opioid receptor types




Receptor	Effect
Mu	Analgesia (medial thalamus)
	Euphoria
	Sedation
	Respiratory Depression (medulla)
	Constipation (GI tract)
	Meosis (substantia nigra)
Kappa	Analgesia (medial thalamus)
	Sedation
	Meosis (substantia nigra)
	Diuresis
Delta	Supraspinal analgesia (medial thalamus)



# Changes In Functional Connections




- Amygdala
  - ↓ functional connectivity with:
    - Insular cortex (emotions)
    - Nucleus accumbens (addiction)
- Nucleus Accumbens-
  - ↓ functional connectivity with:
    - Frontal lobe (decision making)
    - Hippocampus (emotional memories)
    - Amygdala (emotional memories)
    - Periaqueductal gray (brainstem activity)
- VTA
  - Increase in delta receptors, decrease in mu receptors



[http://en.wikipedia.org/wiki/File:Dopamine\\_Pathways.png](http://en.wikipedia.org/wiki/File:Dopamine_Pathways.png)

# Structural and functional connectivity changes from chronic use of Rx opioids



# Conclusions



- Opioid receptor expression is varied with opioid use:
  - ↓ number of mu receptors
    - ✦ Via internalization
  - ↑ number of delta receptors and heterodimerization
- Mesolimbic reward system brain areas: VTA, hippocampus, nucleus accumbens, and amygdala change their connectivity with opioids

# References



- 1. **Bailey CP, and Connor M.** Opioids: cellular mechanisms of tolerance and physical dependence. In: *Curr Opin Pharmacol.* England: 2005, p. 60-68.
- 2. **Bailey CP, Llorente J, Gabra BH, Smith FL, Dewey WL, Kelly E, and Henderson G.** Role of protein kinase C and mu-opioid receptor (MOPr) desensitization in tolerance to morphine in rat locus coeruleus neurons. In: *Eur J Neurosci.* France: 2009, p. 307-318.
- 3. **Barrett K, and Barman S.** Somatosensory Pathways. *Ganong's Review of Medical Physiology* 2010.
- 4. **Barrett K, Barman S, Boitano S, and Brooks H.** Learning, Memory, Language, & Speech. 2010.
- 5. **Brownstein MJ.** A brief history of opiates, opioid peptides, and opioid receptors. *Proc Natl Acad Sci U S A* 90: 5391-5393, 1993.
- 6. **Cao JL, Vialou VF, Lobo MK, Robison AJ, Neve RL, Cooper DC, Nestler EJ, and Han MH.** Essential role of the cAMP-response-element binding protein pathway in opiate-induced homeostatic adaptations of locus coeruleus neurons. In: *Proc Natl Acad Sci U S A.* United States: 2010, p. 17011-17016.
- 7. **Cosgrove KP.** Imaging receptor changes in human drug abusers. *Curr Top Behav Neurosci* 3: 199-217, 2010.
- 8. **Daglish MR, Weinstein A, Malizia AL, Wilson S, Melichar JK, Britten S, Brewer C, Lingford-Hughes A, Myles JS, Grasby P, and Nutt DJ.** Changes in regional cerebral blood flow elicited by craving memories in abstinent opiate-dependent subjects. *Am J Psychiatry* 158: 1680-1686, 2001.
- 9. **Duvauchelle CL, Fleming SM, and Kornetsky C.** DAMGO and DPDPE facilitation of brain stimulation reward thresholds is blocked by the dopamine antagonist cis-flupenthixol. In: *Neuropharmacology.* England: 1997, p. 1109-1114.
- 10. **Franklin TR, Wang Z, Wang J, Sciortino N, Harper D, Li Y, Ehrman R, Kampman K, O'Brien CP, Detre JA, and Childress AR.** Limbic activation to cigarette smoking cues independent of nicotine withdrawal: a perfusion fMRI study. In: *Neuropsychopharmacology.* United States: 2007, p. 2301-2309.
- 11. **Gupta A, Dcaillot FM, and Devi LA.** Targeting opioid receptor heterodimers: Strategies for screening and drug development. *AAPS J* 8: E153-159, 2006.
- 12. **Hamilton R.** Withdraw Principles. *Goldfrank's Toxicologic Emergencies* 2011.
- 13. **Johnson SW, and North RA.** Opioids excite dopamine neurons by hyperpolarization of local interneurons. *J Neurosci* 12: 483-488, 1992.
- 14. **Katzung B, Masters S, and Trevor A.** Drugs of Abuse. In: *Basic & Clinical Pharmacology*, edited by Katzung BMcGraw-Hill, 2009.
- 15. **Koch T, and Holtt V.** Role of receptor internalization in opioid tolerance and dependence. In: *Pharmacol Ther.* England: 2008, p. 199-206.

# References cont.



- 16. **Kochunov P, Thompson PM, Lancaster JL, Bartzokis G, Smith S, Coyle T, Royall DR, Laird A, and Fox PT.** Relationship between white matter fractional anisotropy and other indices of cerebral health in normal aging: tract-based spatial statistics study of aging. In: *Neuroimage*. United States: 2007, p. 478-487.
- 17. **Law PY, Erickson-Herbrandson LJ, Zha QQ, Solberg J, Chu J, Sarre A, and Loh HH.** Heterodimerization of mu- and delta-opioid receptors occurs at the cell surface only and requires receptor-G protein interactions. In: *J Biol Chem*. United States: 2005, p. 11152-11164.
- 18. **Le Bihan D, Mangin JF, Poupon C, Clark CA, Pappata S, Molko N, and Chabriat H.** Diffusion tensor imaging: concepts and applications. In: *J Magn Reson Imaging*. United States: 2001, p. 534-546.
- 19. **Mansour A, Fox CA, Burke S, Meng F, Thompson RC, Akil H, and Watson SJ.** Mu, delta, and kappa opioid receptor mRNA expression in the rat CNS: an in situ hybridization study. *J Comp Neurol* 350: 412-438, 1994.
- 20. **Mickiewicz AL, and Napier TC.** Repeated exposure to morphine alters surface expression of AMPA receptors in the rat medial prefrontal cortex. *Eur J Neurosci* 33: 259-265, 2011.
- 21. **Millan MJ, Czlonkowski A, Lipkowski A, and Herz A.** Kappa-opioid receptor-mediated antinociception in the rat. II. Supraspinal in addition to spinal sites of action. *J Pharmacol Exp Ther* 251: 342-350, 1989.
- 22. **Nelson LS, and Olsen D.** Opioids. *Goldfrank's Toxicologic Emergencies* 2011.
- 23. **O'Brien C.** Drug Addiction and Drug Abuse. *Goodman & Gilman's The Pharmacological Basis of Therapeutics*.
- 24. **Piras AP, Zhou Y, Schlussman SD, Ho A, and Kreek MJ.** Acute withdrawal from chronic escalating-dose binge cocaine administration alters kappa opioid receptor stimulation of [35S] guanosine 5'-O-[gamma-thio]triphosphate acid binding in the rat ventral tegmental area. In: *Neuroscience*. United States: 10 IBRO. Published by Elsevier Ltd, 2010, p. 751-757.
- 25. **Policy OoNDC.** Heroin Facts & Figures. ONDCP, 2008.
- 26. **Quality CfbHSA.** 2004-2009 Emergency Department Detail Table Notes. SAMHSA, Drug Abuse Warning Network, 2009.
- 27. **Trigo JM, Martin-Garcia E, Berrendero F, Robledo P, and Maldonado R.** The endogenous opioid system: a common substrate in drug addiction. In: *Drug Alcohol Depend*. Ireland: 2010, p. 183-194.
- 28. **Upadhyay J, Maleki N, Potter J, Elman I, Rudrauf D, Knudsen J, Wallin D, Pendse G, McDonald L, Griffin M, Anderson J, Nutile L, Renshaw P, Weiss R, Becerra L, and Borsook D.** Alterations in brain structure and functional connectivity in prescription opioid-dependent patients. In: *Brain*. England: 2010, p. 2098-2114.
- 29. **Williams TJ, and Milner TA.** Delta opioid receptors colocalize with corticotropin releasing factor in hippocampal interneurons. In: *Neuroscience*. United States: 2011 IBRO. Published by Elsevier Ltd, 2011, p. 9-22.
- 30. **Yaksh T, and Wallace M.** Opioids, Analgesia, and Pain Management. *Goodman & Gilman's The Pharmacological Basis of Therapeutics* 2011.